Biotech Bubble Watch 2014
With valuations at historic highs, the industry’s bull run is looking frothy. Investors should brace for a correction, though not a 2000-like bust.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.